Promoter of Suven Pharma, Advent International, had said last year that it would merge the two businesses post the buyout of its significant stake in Suven Pharma. Under the merger, shareholders of Cohance will be issued 11 shares of Suven Pharma for every 295 shares held by the former. The new shares of Suven will be traded on the NSE and BSE.
| Subscribe To Our Free Newsletter |
